RLAY
Relay Therapeutics, Inc.
Latest Form 4:Sale$116.4MbySVF Pauling (Cayman) Ltd (10% Owner) · filed Aug 28, 2026
Relay Therapeutics, Inc. (RLAY) has 27 SEC Form 4 filings (44 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Aug 28, 2026.
The most active filer is Chief Financial Officer Catinazzo Thomas with 12 filings. Insiders have net sold $125.8M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Sanjiv K. Patel
- Employees:259
- HQ:Cambridge, MA, US
- IPO:2020-07-16
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$127.6M
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Market Cap
$4.1B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
SVF Pauling (Cayman) LtdFirst filing | 10% Owner | Sale | 6,000,000 | $116.4M | Aug 28 | SEC ↗ |
| See remarks | Sale | 4,508 | $90K | Aug 28 | SEC ↗ | |
| Chief Financial Officer | Sale | 17,717 | $350K | Aug 18 | SEC ↗ | |
| President and CEO | Sale | 48,199 | $980K | Aug 18 | SEC ↗ | |
| Chief Financial Officer | Sale | 1,459 | $27K | Jul 30 | SEC ↗ | |
| See remarks | Sale | 748 | $14K | Jul 30 | SEC ↗ | |
| President, R&D | Sale | 2,237 | $42K | Jul 30 | SEC ↗ | |
| Chief Financial Officer | Sale | 17,717 | $331K | Jul 8 | SEC ↗ | |
| President, R&D | Sale | 8,660 | $162K | Jul 8 | SEC ↗ | |
Patel SanjivFirst in 6 months | President and CEO | Sale | 48,199 | $944K | Jul 8 | SEC ↗ |
| See remarks | Sale | 50,000 | $955K | Jul 2 | SEC ↗ | |
| Chief Financial Officer | Sale | 187,163 | $3.2M | Jun 24 | SEC ↗ | |
| President, R&D | Sale | 93,456 | $1.6M | Jun 24 | SEC ↗ | |
| Chief Financial Officer | Sale | 17,717 | $228K | May 14 | SEC ↗ | |
Bergstrom Donald AFirst in 3 months | President, R&D | Sale | 1,490 | $22K | Apr 30 | SEC ↗ |
| Chief Financial Officer | Sale | 972 | $14K | Apr 30 | SEC ↗ | |
Rahmer PeterFirst in 3 months | See remarks | Sale | 753 | $11K | Apr 30 | SEC ↗ |
| Chief Financial Officer | Sale | 17,717 | $230K | Apr 9 | SEC ↗ | |
| Chief Financial Officer | Sale | 1,800 | $27K | Apr 9 | SEC ↗ | |
| Chief Financial Officer | Sale | 17,717 | $178K | Mar 11 | SEC ↗ | |
Rahmer PeterFirst in 3 months | See remarks | Sale | 11,684 | $89K | Jan 29 | SEC ↗ |
Rahmer PeterFirst in 3 months | See remarks | Sale | 1,354 | $11K | Jan 29 | SEC ↗ |
Bergstrom Donald AFirst in 3 months | President, R&D | Sale | 18,895 | $144K | Jan 29 | SEC ↗ |
Bergstrom Donald AFirst in 3 months | President, R&D | Sale | 2,686 | $23K | Jan 29 | SEC ↗ |
Catinazzo ThomasFirst in 3 months | Chief Financial Officer | Sale | 13,820 | $105K | Jan 29 | SEC ↗ |
Catinazzo ThomasFirst in 3 months | Chief Financial Officer | Sale | 1,695 | $14K | Jan 29 | SEC ↗ |
| President and CEO | Sale | 43,168 | $338K | Jan 7 | SEC ↗ | |
Patel SanjivFirst filing | President and CEO | Sale | 62,073 | $435K | Nov 4 | SEC ↗ |
Rahmer PeterFirst filing | See remarks | Sale | 19,135 | $139K | Oct 30 | SEC ↗ |
Rahmer PeterFirst filing | See remarks | Sale | 21,394 | $160K | Oct 30 | SEC ↗ |
Bergstrom Donald AFirst filing | President, R&D | Sale | 30,897 | $225K | Oct 30 | SEC ↗ |
Catinazzo ThomasFirst filing | Chief Financial Officer | Sale | 21,664 | $158K | Oct 30 | SEC ↗ |
Related companies
Relay Therapeutics, Inc. is in the Healthcare sector.